Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Cadiñanos Loidi J, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Escobar Salinas N, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Gomez Rosso R, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Martínez Robles E, Matteelli A, Mazza-Stalder J, Moschos C, Muñoz-Torrico M, Mustafa Hamdan H, Nakčerienė B, Nicod L, Nieto Marcos M, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Dec 19;54(6). pii: 1901522. doi: 10.1183/13993003.01522-2019. Print 2019 Dec.

PMID:
31601711
2.

Management of patients with multidrug-resistant tuberculosis.

Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Günther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schön T, Tiberi S, Valda J, Yablonskii PK, Dheda K.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662. doi: 10.5588/ijtld.18.0622.

PMID:
31315696
3.

Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 Countries.

Zuur MA, Veenhof H, Aleksa A, Vanʼt Boveneind-Vrubleuskaya N, Darmawan E, Hasnain MG, Heysell SK, Jongedijk EM, Koster RA, Magis-Escurra C, Martinez N, Molinas G, Mondal D, Mulyani UA, Perwitasari DA, Tsivunchyk A, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Dec;41(6):714-718. doi: 10.1097/FTD.0000000000000659.

PMID:
31169760
4.

Outcomes of hypertonic saline inhalation as a treatment modality in nontuberculous mycobacterial pulmonary disease.

Huiberts A, Zweijpfenning SMH, Pennings LJ, Boeree MJ, van Ingen J, Magis-Escurra C, Hoefsloot W.

Eur Respir J. 2019 Jul 11;54(1). pii: 1802143. doi: 10.1183/13993003.02143-2018. Print 2019 Jul. No abstract available.

PMID:
31000680
5.

Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease.

Zweijpfenning SMH, Schildkraut JA, Coolen JPM, Ruesen C, Koenraad E, Janssen A, Ruth MM, de Jong AS, Kuipers S, Aarnoutse RE, Magis-Escurra C, Hoefsloot W, van Ingen J.

Eur Respir J. 2019 Jul 11;54(1). pii: 1900118. doi: 10.1183/13993003.00118-2019. Print 2019 Jul. No abstract available.

PMID:
31000671
6.

Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.

Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, Aarnoutse RE, Magis-Escurra C, Kosterink JGW, van der Werf TS, Alffenaar JC, Sturkenboom MGG.

Clin Pharmacokinet. 2019 Nov;58(11):1445-1454. doi: 10.1007/s40262-019-00763-3.

7.

Nontuberculous mycobacterial pulmonary disease and Aspergillus co-infection: Bonnie and Clyde?

Geurts K, Zweijpfenning SMH, Pennings LJ, Schildkraut JA, Boeree MJ, Magis-Escurra C, van der Lee H, Verweij PE, Hoefsloot W, van Ingen J.

Eur Respir J. 2019 Jul 4;54(1). pii: 1900117. doi: 10.1183/13993003.00117-2019. Print 2019 Jul. No abstract available.

PMID:
30956203
8.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

9.

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.

Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, van Crevel R, Aarnoutse R, Boeree M, Magis-Escurra C.

PLoS One. 2019 Mar 14;14(3):e0213718. doi: 10.1371/journal.pone.0213718. eCollection 2019.

10.

A case promoting use of ultrasound-guided sampling techniques to correctly diagnose MDR-TB in children.

van Aerde KJ, van der Heijden EHFM, Henriet SS, Merkus PJ, Magis-Escurra C, Hoefsloot W, van Ingen J, van der Flier M.

Int J Tuberc Lung Dis. 2019 Feb 1;23(2):236-238. doi: 10.5588/ijtld.18.0322.

PMID:
30808457
11.

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin.

van Beek SW, Ter Heine R, Keizer RJ, Magis-Escurra C, Aarnoutse RE, Svensson EM.

Clin Pharmacokinet. 2019 Jun;58(6):815-826. doi: 10.1007/s40262-018-00732-2.

PMID:
30671890
12.

A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.

Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, Zweijpfenning SMH, Hoefsloot W, Kuipers S, Magis-Escurra C, Wertheim HFL, van Ingen J.

J Antimicrob Chemother. 2019 Apr 1;74(4):935-943. doi: 10.1093/jac/dky526.

PMID:
30649327
13.

Clofazimine does not lead to significant QT interval prolongation: a multicentre study.

Zweijpfenning SMH, van Groningen H, van Ingen J, Magis-Escurra C, Boeree MJ, Wagner D, Bax H, Andrejak C, Wener R, Rahman A, Kunst H, Lorent N, Brouwer MA, Hoefsloot W; NTM-NET.

Eur Respir J. 2018 Nov 1;52(5). pii: 1801386. doi: 10.1183/13993003.01386-2018. Print 2018 Nov. No abstract available.

PMID:
30385602
14.

Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease.

Ruth MM, Sangen JJN, Pennings LJ, Schildkraut JA, Hoefsloot W, Magis-Escurra C, Wertheim HFL, van Ingen J.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01208-18. doi: 10.1128/AAC.01208-18. Print 2018 Oct.

15.

Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.

Martial LC, Kerkhoff J, Martinez N, Rodríguez M, Coronel R, Molinas G, Roman M, Gomez R, Aguirre S, Jongedijk E, Huisman J, Touw DJ, Pérez D, Chaparro G, Gonzalez F, Aarnoutse RE, Alffenaar JW, Magis-Escurra C.

Int J Antimicrob Agents. 2018 Jul;52(1):109-113. doi: 10.1016/j.ijantimicag.2018.04.020. Epub 2018 May 8.

PMID:
29751121
16.

Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; for TBNET.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):379-386. doi: 10.1164/rccm.201710-2141OC.

PMID:
29509468
17.

Pound foolish and penny wise-when will dosing of rifampicin be optimised?

Magis-Escurra C, Anthony RM, van der Zanden AGM, van Soolingen D, Alffenaar JC.

Lancet Respir Med. 2018 Apr;6(4):e11-e12. doi: 10.1016/S2213-2600(18)30044-4. Epub 2018 Jan 29. No abstract available.

PMID:
29396032
18.

Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.

Zweijpfenning S, Kops S, Magis-Escurra C, Boeree MJ, van Ingen J, Hoefsloot W.

Respir Med. 2017 Oct;131:220-224. doi: 10.1016/j.rmed.2017.08.031. Epub 2017 Sep 1.

PMID:
28947034
19.

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ; PanACEA Consortium.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01054-17. doi: 10.1128/AAC.01054-17. Print 2017 Nov.

20.

The potential of a portable, point-of-care electronic nose to diagnose tuberculosis.

Coronel Teixeira R, Rodríguez M, Jiménez de Romero N, Bruins M, Gómez R, Yntema JB, Chaparro Abente G, Gerritsen JW, Wiegerinck W, Pérez Bejerano D, Magis-Escurra C.

J Infect. 2017 Nov;75(5):441-447. doi: 10.1016/j.jinf.2017.08.003. Epub 2017 Aug 10.

PMID:
28804027
21.

Treatment outcomes of MDR-TB and HIV co-infection in Europe.

Magis-Escurra C, Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBnet.

Eur Respir J. 2017 Jun 8;49(6). pii: 1602363. doi: 10.1183/13993003.02363-2016. Print 2017 Jun. No abstract available.

22.

Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.

Dedicoat MJ, Günther G, Crudu V, Duarte R, Gualano G, Magis-Escurra C, Rumetshofer R, Skrahina A, Spinu V, Tiberi S, Viiklepp P, van Leth F, Lange C; for TBNET ‡.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1222-1224. doi: 10.1164/rccm.201612-2585LE. No abstract available.

PMID:
28323453
23.

Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.

van Altena R, Akkerman OW, Alffenaar JC, Kerstjens HA, Magis-Escurra C, Boeree MJ, van Soolingen D, de Lange WC, Bolhuis MS, Hoefsloot W, de Vries G, van der Werf TS.

Eur Respir J. 2016 Dec;48(6):1800-1802. doi: 10.1183/13993003.01208-2016. Epub 2016 Oct 6. No abstract available.

24.

Treatment Outcomes in Multidrug-Resistant Tuberculosis.

Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, Magis-Escurra C, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBNET.

N Engl J Med. 2016 Sep 15;375(11):1103-5. doi: 10.1056/NEJMc1603274. No abstract available.

25.

Deficient interleukin-17 production in response to Mycobacterium abscessus in cystic fibrosis.

Becker KL, van Ingen J, Ten Oever J, Merkus PJ, Ferwerda G, Netea MG, Magis-Escurra C, Reijers MH, van de Veerdonk FL.

Eur Respir J. 2016 Mar;47(3):990-3. doi: 10.1183/13993003.00446-2015. Epub 2016 Jan 7. No abstract available.

26.

Regimens for nontuberculous mycobacterial lung disease lack early bactericidal activity.

Slaats MH, Hoefsloot W, Magis-Escurra C, Boeree MJ, Wattenberg M, Kuipers S, van Ingen J.

Eur Respir J. 2016 Mar;47(3):1000-2. doi: 10.1183/13993003.00925-2015. Epub 2015 Dec 2. No abstract available.

27.

A Step toward an Optimized Rifampin Dose Completed.

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE.

Am J Respir Crit Care Med. 2015 Aug 15;192(4):525-6. doi: 10.1164/rccm.201506-1061LE. No abstract available.

PMID:
26278799
28.

Focused human gene expression profiling using dual-color reverse transcriptase multiplex ligation-dependent probe amplification.

Haks MC, Goeman JJ, Magis-Escurra C, Ottenhoff TH.

Vaccine. 2015 Sep 29;33(40):5282-8. doi: 10.1016/j.vaccine.2015.04.054. Epub 2015 Apr 24.

PMID:
25917681
29.

Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009.

van Altena R, de Vries G, Haar CH, de Lange WC, Magis-Escurra C, van den Hof S, van Soolingen D, Boeree MJ, van der Werf TS.

Int J Tuberc Lung Dis. 2015 Apr;19(4):406-12. doi: 10.5588/ijtld.14.0838.

PMID:
25859995
30.

Bronchiectasis.

Magis-Escurra C, Reijers MH.

BMJ Clin Evid. 2015 Feb 25;2015. pii: 1507. Review.

31.

Multidrug-resistant tuberculosis in Europe, 2010-2011.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, Magis-Escurra C, McLaughlin AM, Muylle I, Polcová V, Pontali E, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; TBNET.

Emerg Infect Dis. 2015 Mar;21(3):409-16. doi: 10.3201/eid2103.141343.

32.

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE; PanACEA Consortium.

Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65. doi: 10.1164/rccm.201407-1264OC.

PMID:
25654354
33.

Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin.

Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R, Boeree MJ, Donders AR, van Altena R, van der Werf TS, Aarnoutse RE.

Int J Antimicrob Agents. 2014 Sep;44(3):229-34. doi: 10.1016/j.ijantimicag.2014.04.019. Epub 2014 Jun 9.

PMID:
24985091
34.

Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients.

Becker KL, Gresnigt MS, Smeekens SP, Jacobs CW, Magis-Escurra C, Jaeger M, Wang X, Lubbers R, Oosting M, Joosten LA, Netea MG, Reijers MH, van de Veerdonk FL.

Clin Exp Allergy. 2015 Feb;45(2):423-37. doi: 10.1111/cea.12354.

PMID:
24912986
35.

Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections.

Magis-Escurra C, Alffenaar JW, Hoefnagels I, Dekhuijzen PN, Boeree MJ, van Ingen J, Aarnoutse RE.

Int J Antimicrob Agents. 2013 Sep;42(3):256-61. doi: 10.1016/j.ijantimicag.2013.05.007. Epub 2013 Jul 7.

PMID:
23837923
36.

Prevalence of nontuberculous mycobacteria in COPD patients with exacerbations.

Hoefsloot W, van Ingen J, Magis-Escurra C, Reijers MH, van Soolingen D, Dekhuijzen RP, Boeree MJ.

J Infect. 2013 Jun;66(6):542-5. doi: 10.1016/j.jinf.2012.12.011. Epub 2013 Jan 5. No abstract available.

PMID:
23298891
37.

The Cough Cylinder: a tool to study measures against airborne spread of (myco-) bacteria.

Vanden Driessche K, Marais BJ, Wattenberg M, Magis-Escurra C, Reijers M, Tuinman IL, Boeree MJ, van Soolingen D, de Groot R, Cotton MF.

Int J Tuberc Lung Dis. 2013 Jan;17(1):46-53. doi: 10.5588/ijtld.12.0289.

PMID:
23232004
38.

Hypersensitivity pneumonitis caused by Mycobacterium avium subsp. hominissuis in a hot tub, as proven by IS1245 RFLP and rep-PCR typing.

van der Zanden RJ, Magis-Escurra C, de Lange WC, Hoefsloot W, Boeree MJ, van Ingen J, van Soolingen D.

Int J Mycobacteriol. 2012 Sep;1(3):152-4. doi: 10.1016/j.ijmyco.2012.07.006. Epub 2012 Aug 24.

39.

Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases.

Hoefsloot W, van Ingen J, Peters EJ, Magis-Escurra C, Dekhuijzen PN, Boeree MJ, van Soolingen D.

Clin Microbiol Infect. 2013 May;19(5):432-7. doi: 10.1111/j.1469-0691.2012.03817.x. Epub 2012 Mar 22.

40.

Therapeutic drug monitoring in the treatment of tuberculosis patients.

Magis-Escurra C, van den Boogaard J, Ijdema D, Boeree M, Aarnoutse R.

Pulm Pharmacol Ther. 2012 Feb;25(1):83-6. doi: 10.1016/j.pupt.2011.12.001. Epub 2011 Dec 11.

PMID:
22179055
41.

Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay.

Joosten SA, Goeman JJ, Sutherland JS, Opmeer L, de Boer KG, Jacobsen M, Kaufmann SH, Finos L, Magis-Escurra C, Ota MO, Ottenhoff TH, Haks MC.

Genes Immun. 2012 Jan;13(1):71-82. doi: 10.1038/gene.2011.64. Epub 2011 Sep 29.

PMID:
21956656
42.

Epidemiology of Mycobacterium bovis disease in humans, The Netherlands, 1993-2007.

Majoor CJ, Magis-Escurra C, van Ingen J, Boeree MJ, van Soolingen D.

Emerg Infect Dis. 2011 Mar;17(3):457-63. doi: 10.3201/eid1703.101111.

43.

The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis.

van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, van Ingen J, Boeree MJ.

PLoS One. 2010 Sep 9;5(9). pii: e12640. doi: 10.1371/journal.pone.0012640.

44.

[Nontuberculous mycobacteria: clinically relevant].

van Ingen J, Hoefsloot W, de Lange WC, Magis-Escurra C, Dekhuijzen PN, Boeree MJ, van Soolingen D.

Ned Tijdschr Geneeskd. 2010;154:A1178. Review. Dutch.

PMID:
20482903
45.

Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis.

Burger DM, Magis-Escurra C, van den Berk GE, Gelinck LB.

AIDS. 2010 Jan 16;24(2):328-30. doi: 10.1097/QAD.0b013e3283350f08. No abstract available.

PMID:
20029272
46.

Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time.

van Ingen J, Verhagen AF, Dekhuijzen PN, van Soolingen D, Magis-Escurra C, Boeree MJ, de Lange WC.

Int J Tuberc Lung Dis. 2010 Jan;14(1):99-105.

PMID:
20003702
47.

[Characteristics and treatment of tuberculosis patients in Dekkerswald, 2000-2005].

Magis-Escurra C, Miedema JR, de Lange WC, van Ingen J, Dekhuijzen PN, Boeree MJ.

Ned Tijdschr Geneeskd. 2008 Mar 15;152(11):622-6. Dutch.

PMID:
18410023
48.

Mycobacterium xenopi clinical relevance and determinants, the Netherlands.

van Ingen J, Boeree MJ, de Lange WC, Hoefsloot W, Bendien SA, Magis-Escurra C, Dekhuijzen R, van Soolingen D.

Emerg Infect Dis. 2008 Mar;14(3):385-9. doi: 10.3201/eid1403.061393.

Supplemental Content

Loading ...
Support Center